HEHyeon-Seok Eom

Hyeon-Seok Eom

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyeon-Seok Eom has a total of 344 co-authors. Here are the top co-authors by number of shared publications:

  • Jin Seok Kim

    Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

    12 shared publications
  • Hyewon Lee

    Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea

    11 shared publications
  • Jongheon Jung

    Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea

    10 shared publications
  • Eunyoung Lee

    Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea

    8 shared publications
  • Cheolwon Suh

    Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    7 shared publications
  • Jae Hoon Lee

    Division of Hematology, Gachon University Medical College, Gachon University Gil Medical Center, Incheon, Republic of Korea

    6 shared publications

Latest Publications

  • Open Access

    Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial

    by Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Hyungwoo Cho, Sang Eun Yoon, Deok Hwan Yang, Ho-Jin Shin, Hyeon-Seok Eom, Eunyoung Lee, Ja Min Byun, et al.

    Anbalcabtagene autoleucel (anbal-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability. We report results from a phase 1 and 2 study in patients with relapsed or refractory large B-cell lymphoma. In phase 2, 79 patients received anbal-cel, and its efficacy was evaluated in 73 patients. The complete response (CR) and partial response rates were 67.1% and 8.2%, respectively. Median progression-free survival (PFS) was 6.04 months (95% confidence interval, 4.34-16.46), and the 6-, 12-, and 18-month PFS rates were 50.9%, 41.1%, and 35.2%, respectively. Median overall survival (OS) was not reached, with 12- and 18-month OS rates of 66.6% and 57.3%, respectively. CAR T-cell expansion (Cmax) was significantly greater in responders than in nonresponders (median Cmax, 20 403 vs 8580 copies per μg). Patients were categorized into long-term response (LR) group or non-LR group based on sustained CR at 6 months. Reduced PD-1 and TIGIT expression on CAR+ T cells was observed in the LR group. Most patients (97.5%) experienced grade ≥3 adverse events, most commonly neutropenia (93.7%), followed by thrombocytopenia (41.8%) and anemia (30.4%). Cytokine release syndrome (CRS) and neurological events occurred in 57.0% and 13.9% of patients, respectively. Grade 3 CRS occurred in 8.9% of patients, with no grade 4 events reported, and grade ≥3 neurological events occurred in 3.8% of patients. Serious infections occurred in 25.3% of patients, including grade 5 infection reported in 3 patients. This trial was registered at www.clinicaltrials.gov as #NCT04836507.


  • Open Access

    Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study

    by Jung Yeon Lee, Suein Choi, Seungpil Jung, Sung-Soo Park, Jin Seok Kim, Seung-Hwan Shin, Young-Woo Jeon, Seung-Ah Yahng, Je-Jung Lee, Hyo Jung Kim, et al.

    Bortezomib-melphalan-prednisone (VMP) is an established induction regimen for transplant-ineligible newly diagnosed multiple myeloma (NDMM), yet optimal post-induction strategies remain unclear. This study evaluated the effectiveness of bortezomib maintenance following VMP using target trial emulation. We compared a prospective maintenance cohort (KMMWP-174 study) with an external control cohort from a multicenter registry. Eligible patients completed 9 VMP cycles, achieved ≥ partial response, and were progression-free for 60 days. The index date was maintenance initiation for cases and day 60 post-VMP for controls. Propensity score matching (1:1) balanced baseline covariates. The primary endpoint was progression-free survival (PFS); overall survival (OS) was secondary. Sensitivity analyses included multivariable regression, landmark analyses, and E-value assessment. Among 178 eligible patients, 60 comprised the maintenance cohort and 118 the control cohort; 54 per group were analyzed after matching. Median PFS was significantly longer with bortezomib maintenance (26.5 vs. 8.8 months; HR 0.437, 95% CI: 0.275–0.694, P < 0.001). PFS benefits were consistent across subgroups, including patients aged ≥ 70 years, those with ISS stage II-III disease, and those with high-risk cytogenetics. OS showed a favorable trend (HR 0.703, P = 0.252). Grade ≥ 3 adverse events occurred in 31.4% (control) and 18.7% (maintenance). No grade ≥ 3 peripheral neuropathy was observed. Bortezomib maintenance following VMP significantly prolonged PFS in transplant-ineligible NDMM with acceptable toxicity. These real-world data support proteasome inhibitor-based maintenance where VMP remains widely used, particularly among older adults with limited treatment options.

  • Open Access

    Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study

    by Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Jae Hoon Lee, Kwai Han Yoo, Young Rok Do, Ho-Jin Shin, Kihyun Kim, Sang Eun Yoon, Dok Hyun Yoon, et al.

    Background: Second salvage autologous stem cell transplantation (SAT) is a therapeutic option for patients with multiple myeloma (MM) who relapse after a first autologous stem cell transplantation (ASCT) in the era of novel agents. However, the clinical context in which SAT provides benefit relative to contemporary salvage regimens remains unclear. Methods: We retrospectively analyzed 51 patients who underwent SAT after novel agent-based induction and first ASCT, and salvage re-induction, and compared outcomes with 113 patients treated with salvage carfilzomib–lenalidomide–dexamethasone (KRd) without SAT. Results: Median interval from first ASCT to relapse was 27 months. In the SAT cohort, median progression-free survival (PFS) and overall survival (OS) from initiation of salvage therapy were 30 and 99 months, respectively. A time to relapse ≥18 months after first ASCT and receipt of SAT as second-line of therapy were associated with significantly longer PFS and OS. In multivariate analysis, administration of SAT at later lines was independently associated with inferior outcomes, while a time to relapse ≥18 months after first ASCT was associated with significantly longer OS. Compared with the KRd-only cohort, SAT was associated with longer OS, whereas PFS was numerically longer without statistical significance. Among patients who had received both a proteasome inhibitor and an immunomodulatory drug as salvage induction, SAT was associated with longer PFS and OS. Conclusions: SAT may provide clinical benefit in selected patients with MM, particularly those with a durable response to first ASCT and those undergoing SAT at an earlier line of relapse in the novel agent era.


  • Open Access

    Seroprevalence of Japanese Encephalitis Virus, and Immunogenicity of the Vero-Cell Culture-Derived Vaccine in Hematopoietic Stem Cell Transplantation Recipients

    by Haejeong Lee, Ji-Man Kang, Minyoung Kim, Hyojung Park, Bonhyang Na, Younhee Park, Jong Gyun Ahn, Eunyoung Lee, Hyewon Lee, Hyeon Jin Park, et al.

    Lee H, et al. J Korean Med Sci. 2026 May;41:e141. https://doi.org/10.3346/jkms.2026.41.e141

  • Open Access

    Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma

    by Jun Ho Yi, Young Hoon Park, Myung-Won Lee, Kwai Han Yoo, Junshik Hong, Hyeon-Seok Eom

    Purpose: Brentuximab vedotin (BV)-based combinations have shown promising results in patients with relapsed or refractory Hodgkin’s lymphoma (RRHL) in Western countries. We conducted a phase II study to further define the role of BV-based salvage therapy in transplant-eligible patients with RRHL in Korea. Methods: Transplant-eligible patients with RRHL were recruited to receive two cycles of BV (1.8 mg/kg) plus DHAP (cisplatin 100 mg/m 2 , cytarabine 2 g/m 2 , and dexamethasone 40 mg). Autologous stem cells were collected from non-progressive patients who received one more cycle of BV-DHAP. After three cycles, the responding patients underwent autologous stem cell transplantation (ASCT). The primary endpoint was a complete metabolic response (CMR) rate after two cycles of BV-DHAP. Results: Between April 2022 and August 2024, seven lymphoma cases were recruited. Owing to slow accrual, the study was terminated early. Their median age was 30 years (range, 24–62 years). All patients received at least two cycles of BV-DHAP; the overall response rate (ORR) was 100%, and four patients showed CMR (57%). One patient withdrew consent after the second cycle, and the other six patients received one more cycle of BV-DHAP, resulting in five patients achieving CMR (71%). One patient failed to receive ASCT, and all five patients who received ASCT achieved post-transplant CMR with a 80% complete response (CR) over a 12-month duration. Thrombocytopenia was the most common grade 3 or higher grade hematologic adverse events ( n = 5). Grade 2 nausea occurred in three patients. Three patients experienced dose reduction, and four patients experienced treatment delays. Conclusions: Despite its encouraging early efficacy, the administration of BV-DHAP in Korean patients with RRHL requires careful monitoring due to toxicity concerns.


  • Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

    by Dong Won Baek, Sang Kyun Sohn, Sung-Hoon Jung, Ga-Young Song, Ik-Chan Song, Jeong Suk Koh, Ho-Jin Shin, Do Young Kim, Sung-Hyun Kim, Ji Hyun Lee, et al.

  • Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study

    by Do Young Kim, Chang-Ki Min, Hyeon-Seok Eom, Jongheon Jung, Kihyun Kim, Jae Hoon Lee, Kwai Han Yoo, Ji Yun Lee, Ja Min Byun, Sung-Hyun Kim, et al.


  • Open Access

    Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study

    by Junghyun Yoon, Jongheon Jung, Boyoung Park, Eunyoung Lee, YoungJu Park, Soomin Yoon, Hyeon-Seok Eom

    The treatment landscape for multiple myeloma (MM) has significantly progressed in recent decades. We analyzed the treatment patterns and clinical outcomes in Korean patients using data from the National Health Insurance Service database. Patients diagnosed with MM between 2010 and 2018 were included. Survival analysis with a Cox regression model was performed. A total of 8,367 patients with MM were identified, from which 2,442 patients underwent stem cell transplantation (SCT). The mean patients’ age at diagnosis was 67.1 years. Since 2011, the combination of a proteasome inhibitor (PI) and an alkylating agent has been most common, with a significant increase in the PI and immunomodulatory drug (IMiD) combination after 2015. The attrition rates after first-line therapy were 45% and 56% for the SCT and non-SCT groups, respectively. Patients on bortezomib, melphalan, and prednisolone were younger with less renal insufficiency compared to those on lenalidomide and dexamethasone. The SCT group had a median overall survival (OS) of 7.04 years, significantly higher than the non-SCT group’s 2.52 years. SCT eligibility and the reimbursement status of new drugs impact the treatment pattern of MM. Expanding access to new agents and identifying patients who can benefit from SCT are essential.


  • Open Access

    Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study

    by Jongheon Jung, Sung-Hoon Jung, Young Rok Do, Ka-Won Kang, Jung Lim Lee, Sung-Soo Yoon, Chang-Ki Min, Hye Jin Kang, Ji Hyun Lee, Ju-Hyun Park, et al.

    Tandem autologous stem cell transplantation can improve the prognosis of patients with multiple myeloma. However, the precise role of tandem transplantation remains debatable. We evaluated the clinical benefits of tandem transplantation retrospectively. Of the 655 included patients, 117 underwent tandem transplantation; the remaining were assigned to the control group. After a single transplantation, the tandem group achieved a complete remission (CR) rate of 24.8%, which increased to 46.2% after a second transplantation. The tandem group had a significantly longer median PFS than the control group in patients with International Staging System (ISS) III and high-risk cytogenetics (23.1 vs. 14.7 months, p = 0.007 for ISS III; 21.7 vs. 13.2 months, p = 0.042 for high-risk cytogenetics). The tandem group exhibited significantly superior PFS to the control group (20.3 vs. 12.6 months, p = 0.003) among patients who failed to achieve CR after a single transplantation. Tandem transplantation was associated with significantly improved PFS after adjusting for maintenance therapy in patients with ISS III, those with high-risk cytogenetics, and those who did not achieve CR after a single transplantation. Following propensity score matching, the tandem group exhibited significantly longer PFS than the control group (30.3 vs. 13.5 months, p = 0.028). Tandem transplantation should be considered in high-risk patients.


  • Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study

    by Boyoung Park, Junghyun Yoon, YooSun Lee, YoungJu Park, Hyeon-Seok Eom

    This is the first study presenting the overall descriptive epidemiology of multiple myeloma (MM), including incidence, mortality rate, and prevalence, in South Korea between 2010 and 2018 based on nationwide medical insurance coverage and mortality statistics data. The incidence of MM between 2010 and 2018 was obtained from nationwide medical claims data, and mortality data were obtained from the Korea National Statistical Office. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) and one- and five-year survival rates of patients with MM each year were estimated. There were 10,835 patients with MM aged ≥ 20 years in South Korea between 2010 and 2018. The ASIR was 2.42/100,000 in 2010 and increased to 2.71/100,000 in 2018, with an annual percent change (APC) of 1.86% (95% CI = 0.74–2.99%, P = 0.005). While this trend was significant in women, it was not statistically significant in men. The ASMR did not significantly change over time. Furthermore, the median survival time of patients with MM diagnosed between 2010 and 2018 was 3.36 years. Notably, the one-year survival rate of patients was increased from 65.3% in 2010 to 76.2% in 2017. Finally, the proportion of patients with MM who received novel therapeutic agents, such as proteasome inhibitors or immunomodulatory drugs, as first-line treatment increased from 37.7% in 2010 to 97.8% in 2018. The ASIR and prevalence of MM in South Korea increased between 2010 and 2018, especially in women and the survival rate of patients with MM has increased.